QQQ   417.36 (-1.43%)
AAPL   165.10 (-1.16%)
MSFT   399.92 (-1.08%)
META   483.53 (-3.64%)
GOOGL   153.94 (-1.33%)
AMZN   174.96 (-2.38%)
TSLA   149.36 (-0.38%)
NVDA   813.39 (-3.94%)
AMD   149.09 (-3.86%)
NIO   3.85 (-3.75%)
BABA   68.86 (-0.03%)
T   16.39 (+0.37%)
F   12.13 (+0.58%)
MU   107.54 (-3.92%)
GE   149.00 (-2.58%)
CGC   8.15 (+4.09%)
DIS   112.12 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   62.18 (+0.13%)
XOM   120.07 (+1.31%)
QQQ   417.36 (-1.43%)
AAPL   165.10 (-1.16%)
MSFT   399.92 (-1.08%)
META   483.53 (-3.64%)
GOOGL   153.94 (-1.33%)
AMZN   174.96 (-2.38%)
TSLA   149.36 (-0.38%)
NVDA   813.39 (-3.94%)
AMD   149.09 (-3.86%)
NIO   3.85 (-3.75%)
BABA   68.86 (-0.03%)
T   16.39 (+0.37%)
F   12.13 (+0.58%)
MU   107.54 (-3.92%)
GE   149.00 (-2.58%)
CGC   8.15 (+4.09%)
DIS   112.12 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   62.18 (+0.13%)
XOM   120.07 (+1.31%)
QQQ   417.36 (-1.43%)
AAPL   165.10 (-1.16%)
MSFT   399.92 (-1.08%)
META   483.53 (-3.64%)
GOOGL   153.94 (-1.33%)
AMZN   174.96 (-2.38%)
TSLA   149.36 (-0.38%)
NVDA   813.39 (-3.94%)
AMD   149.09 (-3.86%)
NIO   3.85 (-3.75%)
BABA   68.86 (-0.03%)
T   16.39 (+0.37%)
F   12.13 (+0.58%)
MU   107.54 (-3.92%)
GE   149.00 (-2.58%)
CGC   8.15 (+4.09%)
DIS   112.12 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   62.18 (+0.13%)
XOM   120.07 (+1.31%)
QQQ   417.36 (-1.43%)
AAPL   165.10 (-1.16%)
MSFT   399.92 (-1.08%)
META   483.53 (-3.64%)
GOOGL   153.94 (-1.33%)
AMZN   174.96 (-2.38%)
TSLA   149.36 (-0.38%)
NVDA   813.39 (-3.94%)
AMD   149.09 (-3.86%)
NIO   3.85 (-3.75%)
BABA   68.86 (-0.03%)
T   16.39 (+0.37%)
F   12.13 (+0.58%)
MU   107.54 (-3.92%)
GE   149.00 (-2.58%)
CGC   8.15 (+4.09%)
DIS   112.12 (-0.28%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   62.18 (+0.13%)
XOM   120.07 (+1.31%)
Free Trial
NASDAQ:KRBP

Kiromic BioPharma (KRBP) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free KRBP Stock Alerts
$2.60
+0.10 (+4.00%)
(As of 10:22 AM ET)
Compare
Today's Range
$2.55
▼
$2.60
50-Day Range
$1.49
▼
$3.46
52-Week Range
$0.16
▼
$8.97
Volume
651 shs
Average Volume
8,539 shs
Market Capitalization
$3.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media
KRBP stock logo

About Kiromic BioPharma Stock (NASDAQ:KRBP)

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

KRBP Stock Price History

KRBP Stock News Headlines

April 10, 2024 | msn.com
Kiromic BioPharma files to withdraw registration statement
April 2, 2024 | businesswire.com
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
March 19, 2024 | finance.yahoo.com
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
March 19, 2024 | businesswire.com
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial
March 1, 2024 | businesswire.com
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
February 28, 2024 | finance.yahoo.com
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
February 28, 2024 | businesswire.com
Kiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7th
April 19, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
February 14, 2024 | finance.yahoo.com
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
February 14, 2024 | businesswire.com
Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
January 29, 2024 | finance.yahoo.com
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
January 5, 2024 | finance.yahoo.com
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
December 14, 2023 | finance.yahoo.com
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
November 16, 2023 | finance.yahoo.com
Kiromic BioPharma Announces Uplisting to OTCQB Market
November 9, 2023 | finance.yahoo.com
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
November 1, 2023 | morningstar.com
Kiromic BioPharma Inc Ordinary Shares
October 23, 2023 | finance.yahoo.com
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
September 15, 2023 | uk.investing.com
Staidson Beijing Biopharma (300204)
September 13, 2023 | finance.yahoo.com
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
July 24, 2023 | finance.yahoo.com
Kiromic BioPharma Welcomes Two New Directors to its Board
June 30, 2023 | marketwatch.com
Kiromic Biopharma Shares Down 12% After Stock Offering Prospectus
June 10, 2023 | bizjournals.com
Founder of multibillion-dollar drug developer Array BioPharma leads Boulder oncology startup in $54M financing round
June 10, 2023 | finance.yahoo.com
KRBP - Kiromic BioPharma, Inc.
June 8, 2023 | theglobeandmail.com
Instrument Name Kiromic Biopharma Inc Instrument Symbol (KRBP-Q)
May 3, 2023 | finance.yahoo.com
What's Going On With Kiromic BioPharma Stock Wednesday
May 1, 2023 | finance.yahoo.com
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
See More Headlines
Receive KRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
4/19/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:KRBP
CUSIP
N/A
CIK
1792581
Web
www.kiromic.com
Phone
832-968-4888
Fax
N/A
Employees
35
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($15.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-20,950,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-125.75%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.22
Quick Ratio
0.22

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($7.25) per share
Price / Book
-0.36

Miscellaneous

Outstanding Shares
1,290,000
Free Float
1,246,000
Market Cap
$3.35 million
Optionable
Not Optionable
Beta
2.00
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Brian Hungerford (Age 48)
    Chief Financial Officer
    Comp: $160.69k
  • Dr. Leonardo Mirandola Ph.D. (Age 42)
    Chief Scientific Officer & Interim COO
    Comp: $383.32k
  • Dr. Scott Dahlbeck M.D. (Age 62)
    Pharm.D., PharmD, Chief of Staff
    Comp: $359.08k

Key Competitors

View All Competitors

KRBP Stock Analysis - Frequently Asked Questions

How have KRBP shares performed in 2024?

Kiromic BioPharma's stock was trading at $0.87 at the beginning of the year. Since then, KRBP shares have increased by 198.9% and is now trading at $2.60.
View the best growth stocks for 2024 here.

When is Kiromic BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our KRBP earnings forecast.

How were Kiromic BioPharma's earnings last quarter?

Kiromic BioPharma, Inc. (NASDAQ:KRBP) released its quarterly earnings results on Monday, March, 18th. The company reported ($4.16) EPS for the quarter.

When did Kiromic BioPharma's stock split?

Shares of Kiromic BioPharma reverse split before market open on Monday, March 13th 2023. The 1-30 reverse split was announced on Monday, March 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Kiromic BioPharma IPO?

Kiromic BioPharma (KRBP) raised $16 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 1,200,000 shares at $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Paulson Investment Company was co-manager.

How do I buy shares of Kiromic BioPharma?

Shares of KRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KRBP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith